PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.
Biochem Pharmacol. 2011 Aug 15;82(4):389-99. doi: 10.1016/j.bcp.2011.05.008. Epub 2011 May 18.
The adenosine A(2B) receptor is of considerable interest as a new drug target for the treatment of asthma, inflammatory diseases, pain, and cancer. In the present study we investigated the role of the cysteine residues in the extracellular loop 2 (ECL2) of the receptor, which is particularly cysteine-rich, by a combination of mutagenesis, molecular modeling, chemical and pharmacological experiments. Pretreatment of CHO cells recombinantly expressing the human A(2B) receptor with dithiothreitol led to a 74-fold increase in the EC(50) value of the agonist NECA in cyclic AMP accumulation. In the C78(3.25)S and the C171(45.50)S mutant high-affinity binding of the A(2B) antagonist radioligand [(3)H]PSB-603 was abolished and agonists were virtually inactive in cAMP assays. This indicates that the C3.25-C45.50 disulfide bond, which is highly conserved in GPCRs, is also important for binding and function of A(2B) receptors. In contrast, the C166(45.45)S and the C167(45.46)S mutant as well as the C166(45.45)S-C167(45.46)S double mutant behaved like the wild-type receptor, while in the C154(45.33)S mutant significant, although more subtle effects on cAMP accumulation were observed - decrease (BAY60-6583) or increase (NECA) - depending on the structure of the investigated agonist. In contrast to the X-ray structure of the closely related A(2A) receptor, which showed four disulfide bonds, the present data indicate that in the A(2B) receptor only the C3.25-C45.50 disulfide bond is essential for ligand binding and receptor activation. Thus, the cysteine residues in the ECL2 of the A(2B) receptor not involved in stabilization of the receptor structure may have other functions.
腺苷 A(2B) 受体作为治疗哮喘、炎症性疾病、疼痛和癌症的新药靶点备受关注。在本研究中,我们通过突变、分子建模、化学和药理学实验的组合,研究了受体富含半胱氨酸的细胞外环 2(ECL2)中的半胱氨酸残基的作用。用二硫苏糖醇预处理重组表达人 A(2B) 受体的 CHO 细胞,导致激动剂 NECA 在环 AMP 积累中的 EC(50) 值增加 74 倍。在 C78(3.25)S 和 C171(45.50)S 突变体中,高亲和力结合 A(2B) 拮抗剂放射性配体 [(3)H]PSB-603 被废除,激动剂在 cAMP 测定中几乎无活性。这表明 GPCR 中高度保守的 C3.25-C45.50 二硫键对于 A(2B) 受体的结合和功能也很重要。相比之下,C166(45.45)S 和 C167(45.46)S 突变体以及 C166(45.45)S-C167(45.46)S 双突变体的行为与野生型受体相似,而在 C154(45.33)S 突变体中观察到对 cAMP 积累的显著影响 - 减少(BAY60-6583)或增加(NECA) - 这取决于所研究的激动剂的结构。与 X 射线结构的密切相关的 A(2A) 受体显示四个二硫键相比,本数据表明在 A(2B) 受体中只有 C3.25-C45.50 二硫键对于配体结合和受体激活是必不可少的。因此,A(2B) 受体 ECL2 中不参与稳定受体结构的半胱氨酸残基可能具有其他功能。